BLACK WEEKSHætteglas −15% · kits −10% · resten −5%med kodeGratis fragt i Tyskland fra €200

Denne side er oversat automatisk og kan indeholde fejl. Har du dansk som modersmål? Vi hører meget gerne din feedback og dine rettelser.Send feedback

The Peptide Desk The Peptide Desk
SR9009, produktfoto
SARMs

SR9009

SARMs

  • Sendes fra Tyskland

Bestilling

Stykpris - Gratis fragt i Tyskland fra 200 € under Black Weeks
  • DHL med sporing
  • Diskret emballage

4.6 ud af 5 på Trustpilot73 anmeldelser

Kort fortalt

SR9009 i tal

Nøgletallene fra vores leksikon.

Hele leksikonopslaget
Class
Rev-erb agonistnot a SARM
Half-life
short
Use
Oralin mg, several times daily
Sizes
10 mg1 size in the shop

Der er endnu ingen laboratorieanalyse for SR9009. Stem på denFå det testet selv, vi betaler halvdelenAlle laboratorieanalyser

Viden

Alt om SR9009

FAQ

Ofte stillede spørgsmål

Kilder til hvert svar: leksikonopslag

Har du stadig et spørgsmål?

Skriv til os, vores team hjælper dig.

Are there studies in humans?

No. As of 26 October 2026 ClinicalTrials.gov lists no trial with SR9009. ChEMBL lists it without a clinical phase. All data come from cell assays and mouse models.

What does SR9009 do?

It activates REV-ERBα and REV-ERBβ, two nuclear receptors of the internal clock. They repress genes, including for fat and cholesterol production. In mice even a single dose changed the daily rhythm of activity and clock genes.

What did the endurance study show?

Muscles without REV-ERBα had fewer mitochondria and worse endurance. Mice injected with SR9009 ran longer and further in the endurance test than the comparison group. The text of the study gives no percentage for this, it is only shown as a chart.

What happened in obese mice?

After 30 days with two injections a day they lost 60 percent more weight than the comparison group and had less fat mass, without eating less. Total cholesterol fell by 47 percent, blood sugar by 19 and triglycerides by 12 percent.

Does SR9009 act only via REV-ERB?

Apparently not. A research group removed REV-ERBα and REV-ERBβ completely from liver and stem cells. SR9009 still reduced cell survival there, changed metabolism and gene reading. According to the authors SR9009 is therefore not a pure stand-in for REV-ERB.

Does it work as a tablet too?

That has not been studied. In the endurance and the obesity study SR9009 was injected into the abdominal cavity. There are no data on oral absorption in humans.

Which side effects are known?

There are no solid data because SR9009 has never been tested in humans. The mouse studies measured effects, not systematic side effects.

Relateret

Relaterede produkter